JP2009537532A - 腫瘍細胞増殖の選択的阻害剤としてのｃｄｋｉ経路阻害剤 - Google Patents

腫瘍細胞増殖の選択的阻害剤としてのｃｄｋｉ経路阻害剤 Download PDF

Info

Publication number
JP2009537532A
JP2009537532A JP2009511024A JP2009511024A JP2009537532A JP 2009537532 A JP2009537532 A JP 2009537532A JP 2009511024 A JP2009511024 A JP 2009511024A JP 2009511024 A JP2009511024 A JP 2009511024A JP 2009537532 A JP2009537532 A JP 2009537532A
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
cdk3
halogens
snx9
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009511024A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009537532A5 (enExample
Inventor
チャン，ベイ−ディー
ロニンソン，イゴール，ビー．
ポーター，ロナルド
Original Assignee
セネックス バイオテクノロジー，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セネックス バイオテクノロジー，インク． filed Critical セネックス バイオテクノロジー，インク．
Publication of JP2009537532A publication Critical patent/JP2009537532A/ja
Publication of JP2009537532A5 publication Critical patent/JP2009537532A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2009511024A 2006-05-15 2007-05-15 腫瘍細胞増殖の選択的阻害剤としてのｃｄｋｉ経路阻害剤 Pending JP2009537532A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74722006P 2006-05-15 2006-05-15
US84996806P 2006-10-06 2006-10-06
PCT/US2007/011622 WO2007133772A2 (en) 2006-05-15 2007-05-15 Cdki pathway inhibitors as selective inhibitors of tumor cell growth

Publications (2)

Publication Number Publication Date
JP2009537532A true JP2009537532A (ja) 2009-10-29
JP2009537532A5 JP2009537532A5 (enExample) 2012-09-20

Family

ID=38694543

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009511024A Pending JP2009537532A (ja) 2006-05-15 2007-05-15 腫瘍細胞増殖の選択的阻害剤としてのｃｄｋｉ経路阻害剤

Country Status (6)

Country Link
US (1) US20080200531A1 (enExample)
EP (1) EP2023925A4 (enExample)
JP (1) JP2009537532A (enExample)
AU (1) AU2007249761A1 (enExample)
CA (1) CA2652339A1 (enExample)
WO (1) WO2007133772A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013541505A (ja) * 2010-08-11 2013-11-14 フィラデルフィア ヘルス アンド エデュケイション コーポレイション ドゥーイング ビジネス アズ ドレクセル ユニバーシティー カレッジ オブ メディシン パーキンソン病におけるジスキネジアを治療するための新規ｄ３ドーパミン受容体アゴニスト

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2853729A1 (en) * 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
CN103468786B (zh) * 2012-06-06 2017-06-13 上海吉凯基因化学技术有限公司 人cdkl3基因的用途及其相关药物
WO2014089450A1 (en) 2012-12-06 2014-06-12 Senex Biotechnology, Inc. Specific inhibitors of cdk3
US10584369B2 (en) * 2013-01-11 2020-03-10 Senex Biotechnology, Inc. Cell-based methods for measuring activity of a protein inhibitor
EP3062791B1 (en) 2013-10-28 2020-01-08 Drexel University Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder
JP7152784B2 (ja) 2017-04-03 2022-10-13 京都薬品工業株式会社 新規サイクリン依存性キナーゼ８及び／又は１９阻害剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540586A (ja) * 2005-05-18 2008-11-20 フォルシュングスフェアブント ベルリン エー ファウ Ａｋａｐ−ｐｋａ相互作用の非ペプチド阻害剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3915990A (en) * 1973-03-13 1975-10-28 Nelson Res & Dev Tryptamines
US5849733A (en) * 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
ES2213996T3 (es) * 1999-12-08 2004-09-01 Centre National De La Recherche Scientifique (Cnrs) Uso de himenialdisina o sus derivados en la fabricacion de medicamentos.
US20070258972A1 (en) * 2003-09-18 2007-11-08 Atadja Peter W Combination of a Histone Deacetylase Inhibitor with a Death Receptor Ligand

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540586A (ja) * 2005-05-18 2008-11-20 フォルシュングスフェアブント ベルリン エー ファウ Ａｋａｐ−ｐｋａ相互作用の非ペプチド阻害剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6012049464; ＹＡＮＧ，Ｓ．　ｅｔ　ａｌ，　Ｃｙｔｏｔｏｘｉｃ　ａｃｔｉｖｉｔｙ　ｏｆ　ｓｏｍｅ　ｉｎｄｏｌｅ　ｄｅｒｉｖａｔｉｖｅｓ　ａｎｄ　ｉｎｄｏｌｅ　ｍｅｔａｂｏｌｉｔｅｓ　ｏｆ　Ｓｔｒｅｐｔｏｍｙｃｅｓ *
JPN7012003864; ＫＡＵ，Ｔ．Ｒ．　ｅｔ　ａｌ，　Ａ　ｃｈｅｍｉｃａｌ　ｇｅｎｅｔｉｃ　ｓｃｒｅｅｎ　ｉｄｅｎｔｉｆｉｅｓ　ｉｎｈｉｂｉｔｏｒｓ　ｏｆ　ｒｅｇｕｌａｔｅｄ　ｎｕｃｌｅａｒ　ｅｘｐｏｒｔ　ｏｆ　ａ　Ｆｏｒ *
JPN7012003865; ＴＡＳＤＥＭＩＲ，　Ｄ．　ｅｔ　ａｌ，　Ｚｅｉｔｓｃｈｒｉｆｔ　ｆｕｅｒ　Ｎａｔｕｒｆｏｒｓｃｈｕｎｇ．　Ｓｅｃｔｉｏｎ　Ｃ．　Ｂｉｏｓｃｉｅｎｃｅｓ，　２００２，　ｖｏｌ．５７，　ｎｏ．９-１０， *
JPN7012003866; ＮＩＣＯＬＡ，　Ｌ，　ｅｔ　ａｌ，　Ｚｅｉｔｓｃｈｒｉｆｔ　ｆｕｅｒ　Ｎａｔｕｒｆｏｒｓｃｈｕｎｇ．　Ｓｅｃｔｉｏｎ　Ｃ．　Ｂｉｏｓｃｉｅｎｃｅｓ，　２００２，　ｖｏｌ．５７，　ｎｏ．１１-１２，　ｐ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013541505A (ja) * 2010-08-11 2013-11-14 フィラデルフィア ヘルス アンド エデュケイション コーポレイション ドゥーイング ビジネス アズ ドレクセル ユニバーシティー カレッジ オブ メディシン パーキンソン病におけるジスキネジアを治療するための新規ｄ３ドーパミン受容体アゴニスト

Also Published As

Publication number Publication date
US20080200531A1 (en) 2008-08-21
WO2007133772A3 (en) 2008-11-20
EP2023925A4 (en) 2011-02-16
EP2023925A2 (en) 2009-02-18
CA2652339A1 (en) 2007-11-22
AU2007249761A1 (en) 2007-11-22
WO2007133772A2 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
JP7323592B2 (ja) 癌を治療するための併用療法
Fedorenko et al. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma
US20100190807A1 (en) CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein
US20080033000A1 (en) Identification of CDKI pathway inhibitors
JP2009537532A (ja) 腫瘍細胞増殖の選択的阻害剤としてのｃｄｋｉ経路阻害剤
JP2010532385A (ja) 複合的癌治療の方法、組成物および標的
AU2014246667A1 (en) Methods of treating diseases characterized by excessive Wnt signalling
Hou et al. The NuRD complex-mediated p21 suppression facilitates chemoresistance in BRCA-proficient breast cancer
Neznanov et al. Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications
KR20110084533A (ko) 암의 치료를 위한 엔자스타우린
US20210137898A1 (en) Methods to treat gliomas using a stat3 inhibitor
KR20180120565A (ko) Alk 저해제에 내성을 획득한 eml4-alk 양성 비소세포폐암의 치료를 위한 약물 선택의 정보 제공 방법
US20240058310A1 (en) Methods of treating diseases and disorders associated with calcium ion signaling
Wang et al. Curaxin CBL0137 Inhibits the Viability of Cancerous Cells in Pre-Clinic Models of MYC-Amplified Medulloblastoma
Ashry et al. Identification of a Proteolysis‐Targeting‐Chimera that Addresses Activated Checkpoint Kinase‐1 Reveals its Non‐Catalytic Functions in Tumor Cells
Kitange et al. CBIO-08. ENDOGENOUS DNA DOUBLE STRAND BREAKS ACTIVATE HETEROGENOUS DNA DAMAGE SIGNALING IN IDH1/2 MUTANT GLIOMAS
HK40061501A (en) Combination therapy for treating cancer
CN102791261A (zh) 用于治疗肾细胞癌的化合物
CN105078983A (zh) 阿司咪唑、其盐或溶剂合物在制备预防和/或治疗恶性淋巴瘤的药物中的用途
PL213249B1 (pl) Zastosowanie pochodnych semikarbazydowych oraz 1,2,4-triazolino-5-onu posiadających układ 1-metylopirolu
Morgan G-Quadruplexes As Molecular Targets For Transcriptional Control
HK1229709B (en) Combination therapy for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120925

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130514